Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Borrows €15M to Launch Novodiag Platform, IVD Tests

NEW YORK (GenomeWeb) – Finnish diagnostics developer Mobidiag Oy announced today that it has elected to borrow €15 million ($16.6 million) from the European Investment Bank Group in order to "finalize and scale up" manufacturing, validation, and commercialization of its PCR- and microarray-based Novodiag platform and in vitro diagnostic tests for infectious agents.

"We have now the resources to reach our goals and build significant value over the next years based on our state-of-the-art assays and platforms," CEO Tuomas Tenkanen said in a statement.

Novodiag is a cartridge-based, multiplex assay platform for the rapid detection of infectious agents and antibiotic resistance. The instrument is aimed at small- to medium-sized clinical microbiology laboratories with lower-throughput requirements. Mobidiag is also developing Novodiag assays for gastrointestinal, respiratory, blood, skin, and central nervous system infections.

The loan comes under the InnovFin initiative and is backed by the European Union under Horizon 2020 financial instruments, Mobidiag said in a statement.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.